To hear about similar clinical trials, please enter your email below
Trial Title:
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
NCT ID:
NCT05594082
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Trastuzumab
Trastuzumab deruxtecan
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
Trastuzumab Deruxtecan
Description:
Trastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
Summary:
The aim of this trial is to explore the real-world effectiveness and poteintial
predictors in Chinese metastatic breast cancer patients.
Criteria for eligibility:
Study pop:
Chinese metastatic breast cancer patients
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Patients aged over 18 years old.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de
novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. Plan to receive or has received Trastuzumab Deruxtecan monotherapy
4. Available medical history.
Exclusion Criteria:
1. Incomplete medical history.
2. Pregnancy or breast-breeding
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fudan University Shanghai Cancer Center
Address:
City:
Shanghai
Zip:
200032
Country:
China
Start date:
November 1, 2021
Completion date:
July 1, 2024
Lead sponsor:
Agency:
Fudan University
Agency class:
Other
Source:
Fudan University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05594082
